Clinical Trial Update: Fluorine-18-α-Methyltyrosine Positron Emission Tomography for Diagnosis and Staging of Lung Cancer

View source ↗

Summary

This completed clinical trial evaluated the diagnostic and staging utility of Fluorine-18-α-Methyltyrosine PET imaging in non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Fluorine-18-α-Methyltyrosine (fluorine-18 alpha-methyltyrosine)

Snippet

Sponsor: Gunma University | Conditions: Carcinoma, Non-Small-Cell Lung | Status: COMPLETED